Equities research analysts predict that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will announce $1.36 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for IDEXX Laboratories’ earnings, with the lowest EPS estimate coming in at $1.36 and the highest estimate coming in at $1.37. IDEXX Laboratories reported earnings per share of $1.23 in the same quarter last year, which would indicate a positive year over year growth rate of 10.6%. The company is expected to issue its next quarterly earnings results on Wednesday, August 7th.

On average, analysts expect that IDEXX Laboratories will report full year earnings of $4.82 per share for the current year, with EPS estimates ranging from $4.80 to $4.86. For the next financial year, analysts forecast that the firm will report earnings of $5.57 per share, with EPS estimates ranging from $5.47 to $5.61. Zacks’ EPS averages are a mean average based on a survey of research firms that follow IDEXX Laboratories.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.13. The company had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. IDEXX Laboratories’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the firm earned $1.01 EPS.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, April 30th. Finally, Canaccord Genuity cut their price objective on shares of IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a report on Tuesday, March 26th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and a consensus price target of $253.50.

In other IDEXX Laboratories news, insider Giovani Twigge sold 1,500 shares of the stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $211.77, for a total value of $317,655.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Jacqueline Studer sold 2,529 shares of the stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $210.57, for a total transaction of $532,531.53. Following the completion of the sale, the vice president now owns 6,918 shares in the company, valued at $1,456,723.26. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,150 shares of company stock valued at $12,754,596. 2.70% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of IDXX. Norges Bank purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $148,632,000. American Century Companies Inc. lifted its stake in IDEXX Laboratories by 111.2% in the 1st quarter. American Century Companies Inc. now owns 1,483,074 shares of the company’s stock worth $331,615,000 after purchasing an additional 780,846 shares in the last quarter. Marshall Wace North America L.P. lifted its stake in IDEXX Laboratories by 1,086.6% in the 1st quarter. Marshall Wace North America L.P. now owns 404,041 shares of the company’s stock worth $90,344,000 after purchasing an additional 369,991 shares in the last quarter. FMR LLC lifted its stake in IDEXX Laboratories by 120.7% in the 4th quarter. FMR LLC now owns 561,266 shares of the company’s stock worth $104,407,000 after purchasing an additional 306,919 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in IDEXX Laboratories by 58.8% in the 4th quarter. Principal Financial Group Inc. now owns 787,832 shares of the company’s stock worth $146,551,000 after purchasing an additional 291,795 shares in the last quarter. Institutional investors and hedge funds own 87.46% of the company’s stock.

IDXX opened at $249.33 on Friday. The company has a market capitalization of $21.39 billion, a P/E ratio of 58.53 and a beta of 0.97. IDEXX Laboratories has a 12 month low of $176.11 and a 12 month high of $256.22. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: What is a trade deficit?

Get a free copy of the Zacks research report on IDEXX Laboratories (IDXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.